Patrick Yeramian joined VGTI Florida® in December 2012 as Medical Director to supervise the design and conduct of therapeutic and vaccine clinical trials. Dr. Yeramian has over 20 years of experience with the clinical development of innovative formulations, new biopharmaceuticals and cellular therapy agents. Dr. Yeramian holds a Medical Degree from the University of Paris together with a Master of Clinical Science in experimental oncology and a Graduate Degree in molecular virology.
He also earned a Master of Business Administration from Rutgers University NJ. Starting in 1987 he served in positions of increasing responsibilities in companies in Europe and since 1992 in the US, where he was a Medical Director for hemato-oncology, infectious diseases and women health at G.D. Searle-Monsanto. In this later position he was instrumental in the clinical development and registration in the US of new products and line extensions in the women health antibiotics and fertility franchise, including Flagyl SR® and Synarel® (a GnRH agonist).
Most recently he was Chief Medical Officer and Vice President Medical Affairs for the Viragen group where he directed the clinical development of Multiferon®, a new interferon drug, until its approval in Europe for treatment of viral hepatitis and malignant melanoma. Since 2000, Dr Yeramian established an independent consulting practice and provided support and guidance to emergent companies in the US and Europe to develop their global registration strategy and implement their US and international clinical plans.